MNPHARM SBC, 1 Imation Way, Oakdale, MN. 55128, USA



The MNPHARM molecular farming process combines technology advances in controlled indoor agriculture, biochemistry and protein purification. Our method for making recombinant proteins in plants is shown below.

Compared to other means of protein production, molecular farming offers the lowest overall cost. Other benefits are very high scale-up capacity, short production times and exceptional product quality. Plants assemble difficult to-make and multi-subunit proteins with proper post-translational modifications for humans. Engineered plants produce glycosylated proteins identical to that obtained from mammalian cell culture, with a low contamination risk from endotoxins, viruses, prions and oncogenic DNA.

MNPHARM, SBC., has exclusive rights to a transient expression platform tailored for high yields of pure protein using transgenic plants. Since researchers can currently pay up to $5000 per milligram for recombinant proteins, our most immediate goal is to build infrastructure and expertise that reduces the cost of recombinant proteins by 100-fold. Detailed techno-economic analyses predict protein production costs of less than $1.00 per milligram at a production scale of 300 kilogram of protein per year. In summary, the major advantages for molecular farminginclude scalability, speed, yield, quality, safety and cost.